Jason Broderick

3 weeks ago | curetoday.com | Jason Broderick

Among patients with EGFR mutation–positive locally advanced or metastatic non–small cell lung cancer (NSCLC), patritumab deruxtecan (HER3-DXd) treatment did not improve overall survival outcomes compared with platinum-based chemotherapy treatment, according to data from the phase 3 HERTHENA-Lung02 study which were shared at the 2025 ASCO Annual Meeting. The median overall survival was 16.0 months in the patritumab deruxtecan arm versus 15.9 months in the chemotherapy arm.

3 weeks ago | targetedonc.com | Jason Broderick

The established safety and efficacy of the alpha-emitting radionuclide radium-223 (Xofigo) in patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases were sustained in 7-year follow-up data from the real-world phase 3 REASSURE trial (NCT02141438), according to findings presented at the 2025 ASCO Annual Meeting.1 At a median follow-up of 17 months (range, 0.3-95.4), 50% of the 1472 patients evaluated in REASSURE had experienced at least 1 adverse event (AE) of...

3 weeks ago | onclive.com | Jason Broderick

The antibody-drug conjugate patritumab deruxtecan (HER3-DXd) did not improve overall survival (OS) compared with platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to results from the phase 3 HERTHENA-Lung02 trial (NCT05338970) presented at the 2025 ASCO Annual Meeting.1 The median OS was 16.0 months (95% CI, 13.7-18.7) in the patritumab deruxtecan arm vs 15.9 months (95% CI, 14.6-17.9) in the...

4 weeks ago | targetedonc.com | Jason Broderick

The next-generation KRAS G12C covalent inhibitor MK-1084 showed promising antitumor activity and a manageable safety profile as a monotherapy and in combination regimens in patients with KRAS G12C–mutated advanced colorectal cancer (CRC), according to results from the phase 1 KANDLELIT-001 (NCT05067283) presented at the 2025 ASCO Annual Meeting.1 At a median follow-up of 23.2 months (range, 0.2-37.7) the confirmed objective response rate (ORR) in patients receiving MK-1084 monotherapy was 38%...

4 weeks ago | targetedonc.com | Jason Broderick

Anlotinib showed noninferior progression-free survival (PFS) vs bevacizumab (Avastin) when either agent was combined with first-line capecitabine/oxaliplatin (CapeOX) chemotherapy in Chinese patients with RAS/BRAF wild-type, unresectable metastatic colorectal cancer (mCRC), meeting the primary end point of the phase 3 ANCHOR trial.1 Results presented at the 2025 ASCO Annual Meeting showed that the median PFS, as assessed by an independent review committee (IRC), was 11.04 months for both...